Literature DB >> 28716816

Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Veronica Lifshitz1, Saul J Priceman2, Wenzhao Li1, Gregory Cherryholmes1, Heehyoung Lee1, Adar Makovski-Silverstein3, Lucia Borriello4, Yves A DeClerck5,6, Hua Yu2.   

Abstract

Drug resistance is a major barrier for the development of effective and durable cancer therapies. Overcoming this challenge requires further defining the cellular and molecular mechanisms underlying drug resistance, both acquired and environment-mediated drug resistance (EMDR). Here, using neuroblastoma (NB), a childhood cancer with high incidence of recurrence due to resistance to chemotherapy, as a model we show that human bone marrow-mesenchymal stromal cells induce tumor expression of sphingosine-1-phosphate receptor-1 (S1PR1), leading to their resistance to chemotherapy. Targeting S1PR1 by shRNA markedly enhances etoposide-induced apoptosis in NB cells and abrogates EMDR, while overexpression of S1PR1 significantly protects NB cells from multidrug-induced apoptosis via activating JAK-STAT3 signaling. Elevated S1PR1 expression and STAT3 activation are also observed in human NB cells with acquired resistance to etoposide. We show in vitro and in human NB xenograft models that treatment with FTY720, an FDA-approved drug and antagonist of S1PR1, dramatically sensitizes drug-resistant cells to etoposide. In summary, we identify S1PR1 as a critical target for reducing both EMDR and acquired chemoresistance in NB. Mol Cancer Ther; 16(11); 2516-27. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28716816      PMCID: PMC5669816          DOI: 10.1158/1535-7163.MCT-17-0379

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  55 in total

Review 1.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 2.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

Review 3.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

4.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

Authors:  S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

Review 6.  Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.

Authors:  Roel H Wilting; Jan-Hermen Dannenberg
Journal:  Drug Resist Updat       Date:  2012-02-20       Impact factor: 18.500

Review 7.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

8.  Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Authors:  Tasnim Ara; Rie Nakata; Michael A Sheard; Hiroyuki Shimada; Ralf Buettner; Susan G Groshen; Lingyun Ji; Hua Yu; Richard Jove; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

Review 9.  Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.

Authors:  Golam Kibria; Hiroto Hatakeyama; Hideyoshi Harashima
Journal:  Arch Pharm Res       Date:  2013-11-23       Impact factor: 4.946

10.  Mechanisms and insights into drug resistance in cancer.

Authors:  Hiba Zahreddine; Katherine L B Borden
Journal:  Front Pharmacol       Date:  2013-03-14       Impact factor: 5.810

View more
  8 in total

Review 1.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

Review 2.  Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications.

Authors:  Caroline Hochheuser; Laurens J Windt; Nina Y Kunze; Dieuwke L de Vos; Godelieve A M Tytgat; Carlijn Voermans; Ilse Timmerman
Journal:  Stem Cells Dev       Date:  2021-01-15       Impact factor: 3.272

3.  Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance.

Authors:  A K M Nawshad Hossian; Fatema Tuz Zahra; Sagun Poudel; Camille F Abshire; Paula Polk; Jone Garai; Jovanny Zabaleta; Constantinos M Mikelis; George Mattheolabakis
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

Review 4.  Mesenchymal Stem/Stromal Cells May Decrease Success of Cancer Treatment by Inducing Resistance to Chemotherapy in Cancer Cells.

Authors:  Taja Železnik Ramuta; Mateja Erdani Kreft
Journal:  Cancers (Basel)       Date:  2022-08-02       Impact factor: 6.575

5.  Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation.

Authors:  Yu-Hang Zhang; Shu-Xiang Cui; Sheng-Biao Wan; Shu-Hua Wu; Xian-Jun Qu
Journal:  Acta Pharmacol Sin       Date:  2020-07-09       Impact factor: 6.150

Review 6.  Bone Marrow Environment in Metastatic Neuroblastoma.

Authors:  Chiara Brignole; Fabio Pastorino; Patrizia Perri; Loredana Amoroso; Veronica Bensa; Enzo Calarco; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

7.  Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.

Authors:  Shikun Yang; Chao Yang; Fei Yu; Wenbing Ding; Yuanchang Hu; Feng Cheng; Feng Zhang; Bugao Guan; Xuehao Wang; Ling Lu; Jianhua Rao
Journal:  Cell Death Dis       Date:  2018-10-30       Impact factor: 8.469

Review 8.  Sphingolipid metabolism in the development and progression of cancer: one cancer's help is another's hindrance.

Authors:  Antonia Piazzesi; Sumaiya Yasmeen Afsar; Gerhild van Echten-Deckert
Journal:  Mol Oncol       Date:  2021-07-29       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.